Metoclopramide inhibits proliferation of leukemia stem cells

January 26, 2021

Chronic myeloid leukemia (CML) results from a degeneration of the hematopoietic stem cells (leukemia stem cells), thereby leading to the uncontrolled formation of specific white blood cells, the so-called granulocytes. Research work at the Department of Medical Oncology at the Inselspital, Bern University Hospital and the University of Bern focused therefore on identifying the signaling pathways and control mechanisms of the leukemia stem cell. A promising approach is provided by working with MPR, an anti-emetic medication commonly used to treat nausea and vomiting.

Specific blocking of leukemia stem cell proliferation with metoclopramide

The exact role of the surface molecule CD93 (cluster of differentiation 93) in controlling the proliferation of leukemia stem cells was analyzed and documented, initially in animal experiments and subsequently in experiments with leukemia stem cells from patients. This revealed a distinct regulatory function of CD93 in leukemia stem cells. To begin with, the effect was demonstrated in vivo in animal experiments. It was further shown that the control function only applies to leukemia stem cells, not to normal hematopoietic stem cells. Furthermore, it was demonstrated that the anti-emetic MPR interrupts the signaling pathway that stimulates cell proliferation of leukemia stem cells in vitro and also, in animal experiments, visibly improves survival with CML by blocking the proliferation of leukemia stem cells. This provides strong evidence that MPR may also show positive results in treating CML in humans.

Extensive research

The study presented in this publication involved exceptionally extensive research. This is also true with regard to the interdisciplinary teams participating from the Department of Medical Oncology, the Department for Biomedical Research, the Institute of Cell Biology and the Department of Orthopedic Surgery and Hematology at the Bern University Hospital and the University of Bern. Prof. Dr. sc. nat. Carsten Riether explains: "In order to develop a new, promising approach to combat CML, contributions from numerous disciplines were necessary and different research approaches had to be pursued. In a screening procedure, we elicited the candidate Metoclopramide and were subsequently able to demonstrate its effect on the CD93 signaling pathway in both in-vitro and in-vivo experiments." The research infrastructure in Bern is optimally designed for such major projects. The expertise in fundamental research at the Department for Biomedical Research (DBMR) and in clinical research at the University Hospital are closely linked and can rapidly produce sound results.

What are the next research activities?

The results have pinpointed CD93 as a specific regulator responsible for leukemia stem cell proliferation. This identifies a promising pathway to targeting leukemia stem cells. Further studies must now prove the clinical effect and relevance. Prof. Adrian Ochsenbein outlines the following picture: "Thanks to this pool of expertise, we were able to identify Metoclopramide as a promising candidate for CML therapy. And with the broad-based research infrastructure and our excellent national and international network, we are hopefully in a position to present clinical results within a reasonable timescale.

Inselspital, Bern University Hospital

Related Signaling Pathway Articles from Brightsurf:

Researchers identify 'druggable' signaling pathway that stimulates lung tissue repair
Researchers at Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries.

Key signaling pathway in the pathogenesis of Paget's disease identified
Researchers from the University of California, Irvine, in collaboration with their colleagues from Beijing, China, have gained new insights into the development of malignant skin cancers collectively known as Paget's disease.

Mouse study shows nerve signaling pathway critical to healing fractures
Sticks and stones may break one's bones, but healing them requires the production of a protein signal that stimulates the generation, growth and spread of vital nerve cells, or neurons, throughout the injured area.

A common insulin signaling pathway across cancer and diabetes
An oncology researcher has made an unexpected contribution to the understanding of type 2 diabetes.

Insects share the same signaling pathway to form their 3-dimensional body
Zoologist shows that beetles, bugs and crickets control their body shape through Fog signalling / publication in 'eLife'.

A new signaling pathway for mTor-dependent cell growth
A team led by the scientist Volker Haucke (Leibniz - Forschungsinstitut für Molekulare Pharmakologie and Freie Universität Berlin) has now discovered how inactivation of a certain lipid kinase promotes mTor complex 1 activity, and may therefore constitute a new point of attack for the treatment of diabetes and cancer.

Chemical probe can regulate signaling pathway and block cell invasion by arboviruses
Dysregulation of the signaling pathway known as the beta-catenin-dependent Wnt can also cause embryo malformation and contribute for the development of breast and cervical cancer.

Important signaling pathway in breast cancer revealed
Researchers at Kanazawa University report in Proceedings of the National Academy of Sciences of the United States of America (PNAS) that a particular signaling pathway in breast-cancer tumors causes cancer cells to divide symmetrically, expanding the tumor.

Colon signaling pathway key to inflammatory bowel disease
Inflammatory bowel disease (IBD) develops because of an uncontrolled immune response in the colon.

Signaling pathways to the nucleus
Researchers have demonstrated how auxin, a hormone that controls many processes in plants, reaches its destination.

Read More: Signaling Pathway News and Signaling Pathway Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to